Prostate Cancer Screening and Diagnoses in the Transfeminine Population

Authors

Alex Stephens, Henry Ford HealthFollow
Chase Morrison, Henry Ford HealthFollow
Jonathan Lutchka, Henry Ford HealthFollow
Caleb Richard, Henry Ford HealthFollow
Keinnan Hares, Henry Ford HealthFollow
Shane Tinsley, Henry Ford HealthFollow
Akshay Sood
Briar Shannon, Henry Ford HealthFollow
Craig G. Rogers, Henry Ford HealthFollow
Jessica E. Shill, Henry Ford HealthFollow
Nabeel A. Shakir, Henry Ford HealthFollow
Firas Abdollah, Henry Ford HealthFollow

Recommended Citation

Stephens A, Morrison C, Lutchka J, Richard C, Hares K, Tinsley S, Sood A, Shannon B, Rogers C, Shill J, Shakir N, and Abdollah F. Prostate Cancer Screening and Diagnoses in the Transfeminine Population. Urology 2024.

Document Type

Article

Publication Date

11-21-2024

Publication Title

Urology

Abstract

OBJECTIVE: To examine the frequency and rate at which transfeminine patients receive prostate-specific antigen testing compared to a matched cisgender cohort.

METHODS: Patients with prostates who had encounters in our health system, are currently age 46 or older, and who are alive were included in our study. Transfeminine patients were identified through diagnosis codes and chart review. A 1:5 matched cohort was created based on patient age, race, and area deprivation index. Conditional logistic regression was done to compare odds of receiving any testing and Poisson regression was done to compare the total tests.

RESULTS: A total of 275,112 patients were included in the study, of which 315 were confirmed to be transfeminine. A well matched 1:5 propensity matched cohort was created. Our results suggest that transfeminine patients were 0.28 (95% CI 0.20 - 0.38, p<0.001) times as likely as cisgender patients to receive at least one PSA test at our institution and received only 32% (95% CI 27%-37%, p <0.001) as many total PSA tests.

CONCLUSION: Until more is known about the best practices for PSA testing in the transfeminine population, these patients should receive PSA testing. However, our results suggest that transfeminine patients are significantly less likely to receive any testing and significantly fewer tests in their lifetimes, which may represent a significant healthcare disparity.

PubMed ID

39580118

ePublication

ePub ahead of print